DOCSLIB.ORG

View Exhibit & Abstract Guide

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
View Exhibit & Abstract Guide EXHIBIT & ABSTRACT GUIDE VISIT US AT BOOTH 105 Merck Biosimilars RENFLEXIS™ is a trademark of Merck Sharp & Dohme Corp. Used under license. © 2017 Merck Canada Inc. All rights reserved BIOSIMILARS Table of Contents Sponsors & Exhibitors 5 Corporate Sponsors 6 Gastro Expo Schedule 8 Floor Plans 9-10 Exhibitor Bios 11-17 2017 CAG Research Program 18 Oral Presentations 21-33 Poster Session I 35-128 Poster Session II 129-221 Author Index 222-229 4 CDDW™ 2018 Sponsors CDDW™ 2018 Exhibitors Affinity Diagnostics Corp. Innomar Strategies Allergan Canada Laborie ALPCO Diagnostics Lupin Pharma Canada Ltd. AMT Surgical McKesson Canada Apollo Endosurgery, Inc. MedReleaf ATGen Canada Inc. Medtronic BioScript Solutions Mylan EPD Boston Scientific Ltd. NKS Health Buhlmann Diagnostic Corp. Oxford University Press, Inc. Canadian Digestive Health Foundation Pendopharm, a division of Pharmascience Celgene Inc. Procter & Gamble Cook Medical Qualisys Diagnostics Inc. Crohn's and Colitis Canada Stanton Territorial Health Authority EndoSoft LLC. Vantage Endoscopy Gastrointestinal Society 5 Benefits of publishing in JCAG: Streamlined Submission: no need to reformat articles for submission Fast Decision Times High Quality and Constructive Peer Review Access to a large audience of gastroenterological professionals including doctors, nurses, researchers, surgeons, and scientists who are dedicated to quality digestive healthcare and the highest ethical standards. Receive regular email alerts as soon as new content is published online. 6 Conference Information Conference Benefits of publishing in JCAG: Streamlined Submission: no need to reformat articles for submission Fast Decision Times High Quality and Constructive Peer Review Access to a large audience of gastroenterological professionals including doctors, nurses, researchers, surgeons, and scientists who are dedicated to quality digestive healthcare and the highest ethical standards. Receive regular email alerts as soon as new content is published online. GASTRO EXPO A GASTRO EXPO B FRIDAY, FEBRUARY 9, 2018 11h45-12h15 11h45-12h15 Intercept Pharma Canada Inc. Allergan (visit booth #108 for more details) Long-term data for obeticholic acid in PBC Vlad Popovic, MD 14h30-15h00 14h30-15h00 Janssen Inc. Olympus Canada Inc. EXITING HELL BAR: A Real Life Patient Story Dr. Remo Advanced Polyp Detection Panaccione Dr. Seth A. Gross, NYU Langone Medical Centre SATURDAY, FEBRUARY 10, 2018 10h30-11h00 10h30-11h00 Janssen Inc. PENTAX Medical (visit booth #116 for more details) LOST AND FOUND: A Real Life Crohn’s Story Dr. Gabor Kandel & Crohn’s and Colitis Canada 12h45-13h15 12h45-13h15 AbbVie Gilead Sciences Canada, Inc. (visit booth #131 for more IBD Research in Canada: Past, Present and Future, details) AbbVie Medical Affairs 15h00-15h30 15h00-15h30 Allergan (visit booth #108 for more details) Takeda Canada, Inc. Case Based Discussions SUNDAY, FEBRUARY 11, 2018 10h30-11h00 Shire Pharma Canada ULC Tips for Managing Patients Requiring IV Hydration Dr. Don Duerksen 12h45-13h15 12h45-13h15 AbbVie Ferring Pharmaceuticals (visit booth #130 for more IBD Research in Canada: Past, Present and Future, details) AbbVie Medical Affairs FLOOR PLAN: MAIN MEZZANINE and CONVENTION FLOOR Main Mezzanine PRINCE CONFEDERATION CONFEDERATION CONFEDERATION TUDOR TUDOR NOVA NEW BRUNSWICK EDWARD 3 5 6 7 8 SCOTIA NFLD SASKATCHEWAN ISLAND ALBERTA MANITOBA QUEBEC CAG STAFF ONLY TERRITORIES BRITISH COLUMBIA ALGONQUIN YORK STATION BAR LIBRARY YORK Convention Floor ONTARIO CONCERT CANADIAN HALL NETWORK CONCERT HALL HALL FOYER CDDW™ REGISTRATION 1 CAG 2 TORONTO SPEAKER SALON B SALON A READY BALLROOM ROOM GALA 9 FLOOR PLAN: NETWORK HALL NETWORK HALL GASTRO EXPO B CDDW™ LOUNGE 124 125 112 118 111 126 113 119 110 127 114 120 109 128 F&B 115 121 F&B 108 129 116 122 107 130 Note: F&B/lounge furniture placement subject to change. 117 123 106 131 54 6 105 132 102 133 134 104 135 AbbVie 102 101 Affinity Diagnostics Corp. 128 136 Allergan Canada 108 103 ALPCO Diagnostics 112 AMT Surgical 133 Apollo Endosurgery, Inc. 125 CDDW™ ATGen Canada Inc. 126 LOUNGE BioScript Solutions 118 GASTRO EXPO A Boston Scientific Ltd. 121 Buhlmann Diagnostic Corp. 135 Canadian Association of Gastroenterology 2 Canadian Digestive Health Foundation 6 Medtronic 103 Celgene Inc. 110 Merck Canada Inc. 105 Cook Medical 113 Mylan EPD 114 Crohn's and Colitis Canada 4 NKS Health 136 EndoSoft LLC. 119 Olympus Canada Inc. 123 Ferring Pharmaceuticals 130 Oxford University Press, Inc. 1 Gastrointestinal Society 5 Pendopharm 129 Gilead Sciences Canada Inc. 131 PENTAX Medical 116 Innomar Strategies 111 Pfizer Canada Inc. 117 Intercept Pharma Canada Inc. 106 Procter & Gamble 122 Janssen Inc. 101 Qualisys Diagnostics Inc. 124 Laborie 109 Shire Pharma Canada ULC 107 Lupin Pharma Canada Ltd. 115 Stanton Territorial Health Authority 120 McKesson Canada 127 Takeda Canada Inc. 104 MedReleaf 132 Vantage Endoscopy 134 10 EXHIBITORS Company: AbbVie like VIBERZI®, CONSTELLA®, ASACOL® 800 and Address: 8401 Trans-Canada SALOFALK®. Additionally, Allergan has an exciting St-Laurent, QC H4S 1Z1 GI pipeline in clinical development, with products for Contact: Chantal Néron gastroparesis, NASH and IBD. Telephone: 888-703-3006 Email: [email protected] Company: Alpco Booth #: 102 Address: 26-G Keewaydin Dr. Salem, NH 03079 USA AbbVie is a global, research-based biopharmaceutical Contact: Bethany Bell company that combines the focus and passion of a Telephone: 800-592-5726 leading-edge biotech with the expertise and structure Email: [email protected] of a long-established pharmaceutical leader. The Booth #: 112 company’s mission is to use its expertise, dedicated people and unique approach to innovation to develop ALPCO offers a wide range of testing solutions, and market advanced therapies that address some of providing scientists and healthcare professionals with the world’s most complex and serious diseases. The vital tools for advancing research and improving quality company has several core areas of focus, including of care. Our product portfolio features immunoassays gastroenterology and hepatitis C. AbbVie aims to to investigate metabolic disorders, celiac disease, IBD help patients live healthier lives and collaborate on sus- and pancreatic insufficiency including: adiponectin, tainable healthcare solutions. For further information, c-peptide, chromogranin A, zonulin, calprotectin, and please visit www.abbvie.ca pancreatic elastase. Additionally, our therapeutic drug monitoring tools can assess response to biologics for Company: AFFINITY Diagnostics Corp. IBD. Address: 194 Wildcat Road Toronto, ON M3J 2N5 Company: AMT Surgical Contact: Daniel Libertucci Address: 20 Steckle Place, Unit 16 Telephone: 416-650-6300 Kitchener, ON N2E 2C3 Email: [email protected] Contact: Amanda Habermehl Booth #: 128 Telephone: 888-803-6799 Email: [email protected] AFFINITY Diagnostics Corp. is a provider of high quality Booth #: 133 in-vitro diagnostic assays for clinical and research laboratory use. Our Featured Products for CDDW Leading the way in safety and performance, AMT is the 2018 are the IDK® CALPROTECTIN ELISA, and the leading supplier of surgical systems in Canada. We fo- PREVENTIS QUANTONCAL point-of-care smartphone cus on providing our customers with surgical solutions device. Fecal Calprotectin is a marker for inflammatory that optimize patient safety, clinical performance, ease and neoplastic gastrointestinal diseases, and is also an of use and cost-effectiveness. ideal marker for therapy monitoring in IBD patients. The IDK® Calprotectin ELISA enables the differential Company: Apollo Endosurgery, Inc. diagnosis between Irritable Bowel Syndrome (IBS) and Address: 1120 S. Capital of Texas Hwy, Bldg. 1, Inflammatory Bowel Disease (IBD). The PREVENTIS Ste. 300 Austin, TX 78746 QUANTONCAL device provides the same perfor- Contact: Sarah Ammons mance as the IDK® Calprotectin ELISA, but with the Telephone: 512-279-5104 added benefits of at-home testing, and smartphone Email: [email protected] integration. At AFFINITY, our commitment to providing Booth #: 125 quality in our products and excellence in our service is the backbone of our business, and the strength of our Apollo Endosurgery, Inc. is a medical device company organization. For more information please e-mail us at: focused on less invasive therapies for the treatment [email protected] of obesity, a condition facing over 600 million people globally, as well as other gastrointestinal disorders. Our Company: Allergan Canada device based therapies are an alternative to invasive Address: 85 Enterprise Blvd., Suite 500 surgical procedures, thus lowering complication rates Markham, ON L6G 0B5 and reducing total healthcare costs. Apollo’s products Contact: Sara Colman are offered in over 80 countries today. Telephone: 800-668-6427 Email: [email protected] Company: ATGen Canada Inc. Booth #: 108 Address: 500 boul. Cartier Ouest, Suite 128 Laval, QC H7V 5B7 Allergan is a global specialty pharmaceutical com- Contact: Gaétan Huneault pany with a full GI portfolio which includes products Telephone: 514-557-2791 11 EXHIBITORS Email: [email protected] COMPANY with highest quality standards and its de- Booth #: 126 termination to increase the knowledge and application of fecal calprotectin (fCAL). BUHLMANN Diagnostics ATGen Canada Inc., is an immunodiagnostic company Corp is the exclusive North American affiliate for focused on the development of in vitro diagnostic BÜHLMANN Laboratories in Switzerland,
Load more

Recommended publications
  • Enteric Alpha Defensins in Norm and Pathology Nikolai a Lisitsyn1*, Yulia a Bukurova1, Inna G Nikitina1, George S Krasnov1, Yuri Sykulev2 and Sergey F Beresten1
    Lisitsyn et al. Annals of Clinical Microbiology and Antimicrobials 2012, 11:1 http://www.ann-clinmicrob.com/content/11/1/1 REVIEW Open Access Enteric alpha defensins in norm and pathology Nikolai A Lisitsyn1*, Yulia A Bukurova1, Inna G Nikitina1, George S Krasnov1, Yuri Sykulev2 and Sergey F Beresten1 Abstract Microbes living in the mammalian gut exist in constant contact with immunity system that prevents infection and maintains homeostasis. Enteric alpha defensins play an important role in regulation of bacterial colonization of the gut, as well as in activation of pro- and anti-inflammatory responses of the adaptive immune system cells in lamina propria. This review summarizes currently available data on functions of mammalian enteric alpha defensins in the immune defense and changes in their secretion in intestinal inflammatory diseases and cancer. Keywords: Enteric alpha defensins, Paneth cells, innate immunity, IBD, colon cancer Introduction hydrophobic structure with a positively charged hydro- Defensins are short, cysteine-rich, cationic peptides philic part) is essential for the insertion into the micro- found in vertebrates, invertebrates and plants, which bial membrane and the formation of a pore leading to play an important role in innate immunity against bac- membrane permeabilization and lysis of the microbe teria, fungi, protozoa, and viruses [1]. Mammalian [10]. Initial recognition of numerous microbial targets is defensins are predominantly expressed in epithelial cells a consequence of electrostatic interactions between the of skin, respiratory airways, gastrointestinal and geni- defensins arginine residues and the negatively charged tourinary tracts, which form physical barriers to external phospholipids of the microbial cytoplasmic membrane infectious agents [2,3], and also in leukocytes (mostly [2,5].
    [Show full text]
  • Downloaded from the Protein Data Bank (PDB
    bioRxiv preprint doi: https://doi.org/10.1101/2021.07.07.451411; this version posted July 7, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. CAT, AGTR2, L-SIGN and DC-SIGN are potential receptors for the entry of SARS-CoV-2 into human cells Dongjie Guo 1, 2, #, Ruifang Guo1, 2, #, Zhaoyang Li 1, 2, Yuyang Zhang 1, 2, Wei Zheng 3, Xiaoqiang Huang 3, Tursunjan Aziz 1, 2, Yang Zhang 3, 4, Lijun Liu 1, 2, * 1 College of Life and Health Sciences, Northeastern University, Shenyang, Liaoning, China 2 Key Laboratory of Data Analytics and Optimization for Smart Industry (Ministry of Education), Northeastern University, Shenyang, Liaoning, China 3 Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, USA 4 Department of Biological Chemistry, University of Michigan, Ann Arbor, USA * Corresponding author. College of Life and Health Sciences, Northeastern University, Shenyang, 110169, China. E-mail address: [email protected] (L. Liu) # These authors contributed equally to this work. 1 bioRxiv preprint doi: https://doi.org/10.1101/2021.07.07.451411; this version posted July 7, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Abstract Since December 2019, the COVID-19 caused by SARS-CoV-2 has been widely spread all over the world.
    [Show full text]
  • A New Vision of Iga Nephropathy: the Missing Link
    International Journal of Molecular Sciences Review A New Vision of IgA Nephropathy: The Missing Link Fabio Sallustio 1,2,* , Claudia Curci 2,3,* , Vincenzo Di Leo 3 , Anna Gallone 2, Francesco Pesce 3 and Loreto Gesualdo 3 1 Interdisciplinary Department of Medicine (DIM), University of Bari “Aldo Moro”, 70124 Bari, Italy 2 Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari “Aldo Moro”, 70124 Bari, Italy; [email protected] 3 Nephrology, Dialysis and Transplantation Unit, DETO, University “Aldo Moro”, 70124 Bari, Italy; [email protected] (V.D.L.); [email protected] (F.P.); [email protected] (L.G.) * Correspondence: [email protected] (F.S.); [email protected] (C.C.) Received: 7 December 2019; Accepted: 24 December 2019; Published: 26 December 2019 Abstract: IgA Nephropathy (IgAN) is a primary glomerulonephritis problem worldwide that develops mainly in the 2nd and 3rd decade of life and reaches end-stage kidney disease after 20 years from the biopsy-proven diagnosis, implying a great socio-economic burden. IgAN may occur in a sporadic or familial form. Studies on familial IgAN have shown that 66% of asymptomatic relatives carry immunological defects such as high IgA serum levels, abnormal spontaneous in vitro production of IgA from peripheral blood mononuclear cells (PBMCs), high serum levels of aberrantly glycosylated IgA1, and an altered PBMC cytokine production profile. Recent findings led us to focus our attention on a new perspective to study the pathogenesis of this disease, and new studies showed the involvement of factors driven by environment, lifestyle or diet that could affect the disease.
    [Show full text]
  • Ontogeny of the Intestinal Circadian Clock and Its Role in the Response to Clostridium Difficile Toxin B
    Ontogeny of the intestinal circadian clock and its role in the response to Clostridium difficile toxin B A dissertation submitted to the Graduate School of the University of Cincinnati in partial fulfilment of the requirements for the degree of Doctor of Philosophy In the Department of Pharmacology & Systems Physiology of the College of Medicine by Andrew Rosselot B.S. Biology, Wittenberg University October 2019 Committee Chair: Christian I. Hong Ph.D. Abstract: The endogenous clock of the intestine regulates physiological processes ranging from nutrient absorption to the pathogenic response. The developmental timepoint when the human intestinal clock becomes active is unknown. We investigated intestinal circadian clock ontogeny using in vitro samples that are representative of distinct developmental timepoints. Induced pluripotent stem cells (iPSCs) were differentiated into 3D human intestinal organoids (HIOs) to mimic intestinal embryonic development in vitro. HIOs were then matured beyond their early fetal state via kidney capsule transplantation. Differentiation of iPSCs into HIOs did not activate robust circadian clock activity. Enteroids isolated from kidney capsule matured HIOs possessed a functional circadian clock, similar to adult biopsy derived human intestinal enteroids (bHIEs). Samples were challenged with toxin B (TcdB) from Clostridium difficile to provide functional insights on intestinal clock activity. The necrotic cell death response to TcdB was clock phase- dependent in samples that possessed an active clock and anti-phasic between mouse enteroids and bHIEs. RNA-seq analysis of mouse enteroids and bHIEs showed both possess robust rhythmic gene expression with up to 20% and 8% of their transcriptome oscillating, respectively. The phase and identity of rhythmic genes was however species-dependent.
    [Show full text]
  • Severity of Experimental Autoimmune Uveitis Is Reduced by Pretreatment with Live Probiotic Escherichia Coli Nissle 1917
    cells Article Severity of Experimental Autoimmune Uveitis Is Reduced by Pretreatment with Live Probiotic Escherichia coli Nissle 1917 Otakar Dusek 1, Alena Fajstova 2, Aneta Klimova 1, Petra Svozilkova 1 , Tomas Hrncir 3 , Miloslav Kverka 2,* , Stepan Coufal 2 , Johan Slemin 2, Helena Tlaskalova-Hogenova 2, John V. Forrester 4,5,6 and Jarmila Heissigerova 1 1 Department of Ophthalmology, First Faculty of Medicine, Charles University and General University Hospital in Prague, 128 08 Prague, Czech Republic; [email protected] (O.D.); [email protected] (A.K.); [email protected] (P.S.); [email protected] (J.H.) 2 Institute of Microbiology of the Czech Academy of Sciences, v.v.i., 142 20 Prague, Czech Republic; [email protected] (A.F.); [email protected] (S.C.); [email protected] (J.S.); [email protected] (H.T.-H.) 3 Institute of Microbiology of the Czech Academy of Sciences, v.v.i., 549 22 Novy Hradek, Czech Republic; [email protected] 4 Section of Immunology and Infection, Institute of Medical Sciences, University of Aberdeen, Aberdeen AB24 3FX, UK; [email protected] 5 Immunology and Virology Program, Centre for Ophthalmology and Visual Science, The University of Western Australia, Crawley, Western Australia 6009, Australia 6 Centre for Experimental Immunology, Lions Eye Institute, Nedlands, Western Australia 6009, Australia * Correspondence: [email protected]; Tel.: +420-24106-2452 Abstract: Non-infectious uveitis is considered an autoimmune disease responsible for a significant burden of blindness in developed countries and recent studies have linked its pathogenesis to dys- regulation of the gut microbiota.
    [Show full text]
  • Inflammatory Bowel Disease
    INFLAMMATORY BOWEL DISEASE Edited by Imre Szabo INFLAMMATORY BOWEL DISEASE Edited by Imre Szabo Inflammatory Bowel Disease http://dx.doi.org/10.5772/46222 Edited by Imre Szabo Contributors Hyunjo Kim, Rahul Anil Sheth, Michael Gee, Valeriu Surlin, Adrian Saftoiu, Catalin Copaescu, Diehl, Yves-Jacques Schneider, Alina Martirosyan, Madeleine Polet, Alexandra Bazes, Thérèse Sergent, Ladislava Bartosova, Michal Kolorz, Milan Bartos, Katerina Wroblova, Michael Wannemuehler, Albert E. Jergens, Amanda E. Ramer-Tait, Anne-Marie C. Overstreet, Brankica Mijandrusic Sincic, Ana Brajdić Published by InTech Janeza Trdine 9, 51000 Rijeka, Croatia Copyright © 2012 InTech All chapters are Open Access distributed under the Creative Commons Attribution 3.0 license, which allows users to download, copy and build upon published articles even for commercial purposes, as long as the author and publisher are properly credited, which ensures maximum dissemination and a wider impact of our publications. After this work has been published by InTech, authors have the right to republish it, in whole or part, in any publication of which they are the author, and to make other personal use of the work. Any republication, referencing or personal use of the work must explicitly identify the original source. Notice Statements and opinions expressed in the chapters are these of the individual contributors and not necessarily those of the editors or publisher. No responsibility is accepted for the accuracy of information contained in the published chapters. The publisher assumes no responsibility for any damage or injury to persons or property arising out of the use of any materials, instructions, methods or ideas contained in the book.
    [Show full text]
  • Expression and Function of Host Defense Peptides at Inflammation
    International Journal of Molecular Sciences Review Expression and Function of Host Defense Peptides at Inflammation Sites Suhanya V. Prasad, Krzysztof Fiedoruk , Tamara Daniluk, Ewelina Piktel and Robert Bucki * Department of Medical Microbiology and Nanobiomedical Engineering, Medical University of Bialystok, Mickiewicza 2c, Bialystok 15-222, Poland; [email protected] (S.V.P.); krzysztof.fi[email protected] (K.F.); [email protected] (T.D.); [email protected] (E.P.) * Correspondence: [email protected]; Tel.: +48-85-7485483 Received: 12 November 2019; Accepted: 19 December 2019; Published: 22 December 2019 Abstract: There is a growing interest in the complex role of host defense peptides (HDPs) in the pathophysiology of several immune-mediated inflammatory diseases. The physicochemical properties and selective interaction of HDPs with various receptors define their immunomodulatory effects. However, it is quite challenging to understand their function because some HDPs play opposing pro-inflammatory and anti-inflammatory roles, depending on their expression level within the site of inflammation. While it is known that HDPs maintain constitutive host protection against invading microorganisms, the inducible nature of HDPs in various cells and tissues is an important aspect of the molecular events of inflammation. This review outlines the biological functions and emerging roles of HDPs in different inflammatory conditions. We further discuss the current data on the clinical relevance of impaired HDPs expression in inflammation and selected diseases. Keywords: host defense peptides; human antimicrobial peptides; defensins; cathelicidins; inflammation; anti-inflammatory; pro-inflammatory 1. Introduction The human body is in a constant state of conflict with the unseen microbial world that threatens to disrupt the host cell function and colonize the body surfaces.
    [Show full text]
  • Alpha-Defensin 5 Expression Is Regulated by Micrornas in the Caco-2 Intestinal Epithelial Cell Line
    HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author J Inflamm Manuscript Author Bowel Dis Disord Manuscript Author . Author manuscript; available in PMC 2016 August 10. Published in final edited form as: J Inflamm Bowel Dis Disord. 2016 April ; 1(1): . Alpha-Defensin 5 Expression is Regulated by microRNAs in the Caco-2 Intestinal Epithelial Cell Line Donald R B Miles1, Jun Shen2, Alice Y. Chuang2, Fenshi Dong2, Feng Wu3, and John Kwon3,* 1Johns Hopkins School of Medicine, USA 2University of Chicago, USA 3University of Texas, Southwestern Medical Center, USA Abstract Background—In inflammatory bowel disease (IBD), an inappropriate immune response leads to chronic mucosal inflammation. This response may be partly due to dysregulation of defensins, which are endogenously produced antimicrobial peptides. This study determined whether microRNAs (miRNAs) regulate α-defensin 5 (DEFA5), which could further implicate both in IBD pathogenesis. Methods—Induction of DEFA5 mRNA and protein expression was determined in Caco-2 cells. An in silico analysis identified putative miRNA binding sites of DEFA5. Expression of these miRNAs was assessed in Caco-2 cells. Regulation of DEFA5 expression by these miRNAs was measured by luciferase assays. Caco-2 cells were transfected with miR-124 and miR-924 mimics, and DEFA5 mRNA and protein expression was measured. Results—DEFA5 mRNA and protein expression was inducible in Caco-2 cells. Fifteen putative miRNA binding sites were found in DEFA5. The expression of miR-124 and miR-924 decreased following induction. Transfection of a luciferase construct containing the DEFA5 miRNA binding sites resulted in a decrease in luciferase activity compared to transfection of the empty vector.
    [Show full text]
  • Defensin–Encoding DEFA1A3 Associate with Urinary Tract Infection Risk in Children with Vesicoureteral Reflux
    CLINICAL RESEARCH www.jasn.org Polymorphisms in a-Defensin–Encoding DEFA1A3 Associate with Urinary Tract Infection Risk in Children with Vesicoureteral Reflux † ‡ Andrew L. Schwaderer,* Huanyu Wang,* SungHwan Kim, Jennifer M. Kline, Dong Liang,§ | † Pat D. Brophy, Kirk M. McHugh,¶ George C. Tseng, Vijay Saxena,* Evan Barr-Beare,* †† ‡ Keith R. Pierce,§ Nader Shaikh,** J. Robert Manak, Daniel M. Cohen, Brian Becknell,* ‡‡ || John D. Spencer,* Peter B. Baker, Chack-Yung Yu,§§ and David S. Hains§ *The Centers for Clinical and Translational Medicine and §§Molecular and Human Genetics, The Research Institute at Nationwide Children’s Hospital, Columbus, Ohio; Departments of †Biostatistics and **Pediatrics, University of Pittsburgh, Pittsburgh, Pennsylvania; ‡Emergency Medicine and ‡‡Department of Pathology, Nationwide Children’s Hospital, Columbus, Ohio; §Innate Immunity Translational Research Center, Children’s Foundation Research Institute at Le Bonheur Children’s Hospital, Memphis, Tennessee; |Division of Nephrology, Department of Pediatrics, University of Iowa Children’s Hospital, Iowa City, Iowa; ¶Division of Anatomy, The Ohio State University, Columbus, Ohio; ††Departments of Biology and Pediatrics, University of Iowa, Iowa; and ||Department of Pediatrics, University of Tennessee Health Science Center, Memphis, Tennessee ABSTRACT The contribution of genetic variation to urinary tract infection (UTI) risk in children with vesicoureteral reflux is largely unknown. The innate immune system, which includes antimicrobial peptides, such as the a-defensins, encoded by DEFA1A3, is important in preventing UTIs but has not been investigated in the vesicoureteral reflux population. We used quantitative real–time PCR to determine DEFA1A3 DNA copy numbers in 298 individuals with confirmed UTIs and vesicoureteral reflux from the Randomized Interven- tion for Children with Vesicoureteral Reflux (RIVUR) Study and 295 controls, and we correlated copy numbers with outcomes.
    [Show full text]
  • Β-Defensin Expression in the Canine Nasal Cavity by Michelle Satomi
    β-defensin expression in the canine nasal cavity by Michelle Satomi Aono A thesis submitted to the Graduate Faculty of Auburn University in partial fulfillment of the requirements for the Degree of Masters of Science Auburn, Alabama May 6th, 2013 Keywords: defensin, innate immunity, canine nasal cavity Copyright 2013 by Michelle S. Aono Approved by Edward E. Morrison, Professor and Head of Anatomy, Physiology and Pharmacology Robert Kemppainen, Associate Professor of Anatomy, Physiology and Pharmacology John C. Dennis, Research Fellow IV of Anatomy, Physiology and Pharmacology Abstract Defensins are a family of endogenous antibiotics that are important in mucosal innate immunity, but little is currently known about defensin expression in the nasal cavity. Herein expression of canine β-defensin (cBD)1, cBD103, cBD108 and cBD123 RNA in the respiratory epithelium (RE), cBD1 and 108 RNA in the olfactory epithelium (OE), and cBD1, cBD108, cBD119 and cBD123 RNA in the olfactory bulb (OB) is reported. cBD1 and 103 were also expressed in the canine nares and tongue. cBD102, cBD120, and cBD122 RNA expression was undetectable in the tissues examined. cBD103 transcript abundance in canine nares showed a 90 fold range of inter-individual variation. Murine β-defensin 14 expression mirrors that of cBD103 in the dog, with high expression in the nares and tongue, but has little to no expression in the RE, OE or OB. High expression of cBD103 in the nares may provide indirect protection to the OE by eliminating pathogens in the rostral portion of the nasal cavity, whereas cBD1 and 108 may provide direct protection to the RE and OE.
    [Show full text]
  • Investigating the Effects of Chronic Perinatal Alcohol and Combined
    www.nature.com/scientificreports OPEN Investigating the efects of chronic perinatal alcohol and combined nicotine and alcohol exposure on dopaminergic and non‑dopaminergic neurons in the VTA Tina Kazemi, Shuyan Huang, Naze G. Avci, Yasemin M. Akay & Metin Akay* The ventral tegmental area (VTA) is the origin of dopaminergic neurons and the dopamine (DA) reward pathway. This pathway has been widely studied in addiction and drug reinforcement studies and is believed to be the central processing component of the reward circuit. In this study, we used a well‑ established rat model to expose mother dams to alcohol, nicotine‑alcohol, and saline perinatally. DA and non‑DA neurons collected from the VTA of the rat pups were used to study expression profles of miRNAs and mRNAs. miRNA pathway interactions, putative miRNA‑mRNA target pairs, and downstream modulated biological pathways were analyzed. In the DA neurons, 4607 genes were diferentially upregulated and 4682 were diferentially downregulated following nicotine‑alcohol exposure. However, in the non‑DA neurons, only 543 genes were diferentially upregulated and 506 were diferentially downregulated. Cell proliferation, diferentiation, and survival pathways were enriched after the treatments. Specifcally, in the PI3K/AKT signaling pathway, there were 41 miRNAs and 136 mRNAs diferentially expressed in the DA neurons while only 16 miRNAs and 20 mRNAs were diferentially expressed in the non‑DA neurons after the nicotine‑alcohol exposure. These results depicted that chronic nicotine and alcohol exposures during pregnancy diferentially afect both miRNA and gene expression profles more in DA than the non‑DA neurons in the VTA. Understanding how the expression signatures representing specifc neuronal subpopulations become enriched in the VTA after addictive substance administration helps us to identify how neuronal functions may be altered in the brain.
    [Show full text]
  • Searching for Rare Variants Associated with Osahs-Related Phenotypes
    SEARCHING FOR RARE VARIANTS ASSOCIATED WITH OSAHS-RELATED PHENOTYPES THROUGH PEDIGREES by JINGJING LIANG Dissertation Advisor: Dr. Xiaofeng Zhu Department of Population and Quantitative Health Sciences CASE WESTERN RESERVE UNIVERSITY May 29, 2019 CASE WESTERN RESERVE UNIVERSITY SCHOOL OF GRADUATE STUDIES We hereby approve the thesis/dissertation of Jingjing Liang candidate for the degree of Ph.D Committee Chair Scott M. Williams Committee Member Jonathan L. Haines Committee Member Xiaofeng Zhu Committee Member Rong Xu Committee Member Curtis M. Tatsuoka Date of Defense January 29, 2019 *We also certify that written approval has been obtained for any proprietary material contained therein. 1 Table of Contents CHAPTER 1: LITERATURE REVIEW AND SPECIFIC AIMS ………………14 1.1 Obstructive sleep apnea-hypopnea syndrome …………………………………..14 1.2 AHI and SpO2 …………………………………………………………………...16 1.3 Rare variants and missing heritability …………………………………………..22 1.4 Rare variant association analysis ...………………………………………………24 1.5 Rare variant test using pedigree………………………………………………….27 1.6 Annotating variants in genetic regions ………………………………………….29 1.7 Mendelian randomization………………………………………………………..32 1.8 Specific aims ……………………………………………………………………36 CHAPTER 2: IDENTIFYING LOW FREQUENCY AND RARE VARIANTS ASSOCIATED WITH AVSPO2S USING PEDIGREES .…….………38 2.1 Introduction ……………………………………………………………………...38 2.2 Material and methods……………………………………………………………..42 2.2.1 Description of study samples…..……………………………………………..42 2.2.2 Overview of the method………………………………………………………45 2.2.3 Primary
    [Show full text]